Cargando…

Donor Bone Marrow-Derived T Cells Inhibit GVHD Induced by Donor Lymphocyte Infusion in Established Mixed Allogeneic Hematopoietic Chimeras

Delayed administration of donor lymphocyte infusion (DLI) to established mixed chimeras has been shown to achieve anti-tumor responses without graft-vs.-host disease (GVHD). Herein we show that de novo donor BM-derived T cells that are tolerant of the recipients are important in preventing GVHD in m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hui, Yang, Yanping, Wang, Guanjun, Wang, Shumei, Yeap, Beow Yong, Sykes, Megan, Yang, Yong-Guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471915/ https://www.ncbi.nlm.nih.gov/pubmed/23077554 http://dx.doi.org/10.1371/journal.pone.0047120

Ejemplares similares

Donor‐derived M2 macrophages attenuate GVHD after allogeneic hematopoietic stem cell transplantation
por: Hanaki, Ryo, et al.
Publicado: (2021)

Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation
por: Ash, S, et al.
Publicado: (2010)

Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
por: Song, Yuan, et al.
Publicado: (2020)

Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation
por: Szyska, Martin, et al.
Publicado: (2016)

Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation
por: Mohammadpour, Hemn, et al.
Publicado: (2023)

Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD
por: He, Fiona, et al.
Publicado: (2016)

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
por: Schmid, Christoph, et al.
Publicado: (2021)

MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML
por: Teich, Katrin, et al.
Publicado: (2023)

Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome
por: Park, Silvia, et al.
Publicado: (2021)

Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
por: Liberatore, Carmine, et al.
Publicado: (2022)

Donor–Recipient Story in Allogeneic Hematopoietic Stem Cell Transplantation
por: Kum, Elena, et al.
Publicado: (2021)

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
por: Alvarez, Maite, et al.
Publicado: (2021)

P1365: DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULTS FROM A RETROSPECTIVE STUDY
por: Rochate, D., et al.
Publicado: (2022)

Optic neuropathy associated with GVHD after bone marrow allogeneic hematopoietic stem cell transplantation for B-Acute lymphoblastic leukemia: case report
por: Wang, Bowen, et al.
Publicado: (2022)

Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
por: Zhang, Binglei, et al.
Publicado: (2021)

An Experience of Donor Lymphocyte Infusion after Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease
por: Rostami, Tahereh, et al.
Publicado: (2020)

Predicting Successful Hematopoietic Stem Cell Collection in Healthy Allogeneic Donors
por: Kayser, Sabine, et al.
Publicado: (2023)

Donor Cell Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation
por: Khattab, Ahmed, et al.
Publicado: (2023)

Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation
por: Teshima, Takanori, et al.
Publicado: (2023)

Harnessing allogeneic NK cells: improving outcomes with tailored donor lymphocyte infusion
por: McCurdy, Shannon R.
Publicado: (2022)

Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells
por: Kwon, Yong-Rim, et al.
Publicado: (2020)

Neither COVID-19, Nor Cryopreservation, Prevented Allogeneic Product Infusion: A Report from the National Marrow Donor Program
por: Stefanski, Heather E., et al.
Publicado: (2021)

Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: A report from the National Marrow Donor Program
por: Farhadfar, Nosha, et al.
Publicado: (2022)

Is It Better to Mobilize Hematopoietic Stem Cells With Pegfilgrastim in Healthy Donors During Allogeneic Hematopoietic Stem Cell Transplantation?
por: Li, Jiali, et al.
Publicado: (2020)

High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group
por: El Jurdi, Najla, et al.
Publicado: (2021)

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor
por: Devillier, Raynier, et al.
Publicado: (2021)

A case of donor-derived granulocytic sarcoma after allogeneic hematopoietic stem cell transplantation
por: Jeong, Seong Hyun, et al.
Publicado: (2010)

Acute intestinal GVHD following donor-derived CD7-CAR-T-cell infusion in a child with Omicron COVID-19
por: Lian, Yu, et al.
Publicado: (2023)

Pediatric donor cell leukemia after allogeneic hematopoietic stem cell transplantation in AML patient from related donor
por: Bobadilla-Morales, Lucina, et al.
Publicado: (2015)

Donor bone marrow–derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice
por: Adams, Rachael C., et al.
Publicado: (2022)

Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation
por: Morin-Zorman, Sarah, et al.
Publicado: (2016)

The Effect of the COVID-19 Pandemic on Unrelated Allogeneic Hematopoietic Donor Collections and Safety
por: Parmar, Gaganvir, et al.
Publicado: (2023)

Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program
por: Yang, Fan, et al.
Publicado: (2017)

Modulation of Allogeneic CD8(+) T-Cell Response by DZNep Controls GVHD While Preserving Hematopoietic Chimerism
por: Wang, Jina, et al.
Publicado: (2013)

Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation
por: Zhao, Peng, et al.
Publicado: (2021)

Donor T-Cell Repertoire Profiling in Recipient Lymphoid and Parenchyma Organs Reveals GVHD Pathogenesis at Clonal Levels After Bone Marrow Transplantation in Mice
por: Wu, Yongxia, et al.
Publicado: (2021)

Post-Transplant Cyclophosphamide and Tacrolimus—Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors
por: Carnevale-Schianca, Fabrizio, et al.
Publicado: (2021)

The Addition of Sirolimus to GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Efficacy and Safety
por: Chen, Xiaoli, et al.
Publicado: (2021)

Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation
por: Hahn, Theresa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gi96apd949941biookue2t2iq8